FOXO4-DRI
RecoveryPreclinicalAlso known as: FOXO4
FOXO4-DRI is a synthetic 34-amino-acid D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53, with the specific goal of inducing apoptosis selectively in senescent cells. The compound was developed by the laboratory of Peter de Keizer at Erasmus Medical Center and reported in a landmark 2017 Cell paper that demonstrated FOXO4-DRI administration to aged mice produced measurable reductions in senescent cell burden, restored renal function, improved fur density and grooming behavior, and extended several markers of organismal health without apparent toxicity at effective doses (Baar et al., 2017).
Overview
At A Glance
FOXO4-DRI works by disrupting the protein-protein interaction between FOXO4 (Forkhead box O4) and p53 in senescent cells, which releases p53 from nuclear sequestration and allows it to translocate to the mitochondrial outer membrane where it triggers the intrinsic apoptosis pathw…
Mechanism of Action
FOXO4-DRI works by disrupting the protein-protein interaction between FOXO4 (Forkhead box O4) and p53 in senescent cells, which releases p53 from nuclear sequestration and allows it to translocate to the mitochondrial outer membrane where it triggers the intrinsic apoptosis pathway (Baar et al., 2017). The mechanism is specific to senescent cells because of a confluence of features that distinguish senescent from non-senescent cells: senescent cells have high baseline expression of p53 (driven by DNA damage and oncogenic signaling), they have accumulated pro-apoptotic mitochondrial priming, they depend on continuous sequestration of p53 in FOXO4-containing foci to avoid death, and they have upregulated FOXO4 specifically as part of the senescence program. Non-senescent cells may express FOXO4 and p53 but at lower levels and without the mitochondrial priming that makes p53 release lethal. Disrupting the FOXO4-p53 interaction therefore produces selective apoptosis in senescent cells without significant effects on their healthy neighbors, a property that is the defining requirement for a useful senolytic. The FOXO4-DRI peptide itself is a 34-amino-acid sequence with D-amino acids in reverse order (the "D-retro-inverso" construction) that recapitulates the three-dimensional binding surface of the native FOXO4 region that interacts with p53. The DRI construction provides two practical advantages: protease resistance (D-amino acids are not cleaved by human proteases that evolved to cut L-amino acid peptide bonds), which extends in vivo half-life from minutes to hours; and cell permeability, because the specific DRI sequence includes properties that allow it to cross plasma membranes without requiring specialized delivery systems (Bourgeois & Madl, 2018). Once inside cells, FOXO4-DRI competes with endogenous FOXO4 for p53 binding in the nucleus, but because the DRI peptide cannot productively sequester p53 (it lacks the downstream signaling features of full-length FOXO4), the net effect is release of p53 from FOXO4 association and subsequent p53 relocation to mitochondria. At mitochondria, p53 directly interacts with anti-apoptotic Bcl-2 family proteins (Bcl-XL, Bcl-2) and promotes Bax and Bak activation, producing outer mitochondrial membrane permeabilization, cytochrome c release, caspase activation, and apoptosis. The selectivity profile of FOXO4-DRI for senescent cells is the key therapeutic feature. In cell culture experiments with mixed populations of senescent and non-senescent fibroblasts, exposure to FOXO4-DRI produces substantial death in the senescent fraction while leaving non-senescent cells largely intact (Baar et al., 2017). In vivo studies in naturally aged mice and in chemotherapy-induced premature senescence models have shown that FOXO4-DRI administration reduces markers of senescent cell burden (SA-beta-gal staining, p21 and p16 expression, SASP factors) in multiple tissues including kidney, liver, fur follicles, and muscle, while sparing tissue architecture and function. The improvements in organismal phenotype — better fur density, improved renal function on creatinine and other markers, increased grooming and exploratory behavior — track with the reductions in tissue senescence burden and support the mechanistic model that senescent cell elimination mediates the organismal benefits. Beyond the core FOXO4-p53 mechanism, FOXO4-DRI administration produces several downstream consequences that may contribute to its effects. Removal of senescent cells reduces the local SASP burden, which allows neighboring non-senescent cells to recover function. Clearance of senescent cells may allow tissue stem cells to re-enter cycles of division and differentiation that had been inhibited by SASP-mediated signals. Altered inflammatory signaling affects systemic markers of inflammaging, the low-grade chronic inflammation that characterizes advanced age. The mechanism does have theoretical and practical limitations. Not all senescent cells depend on FOXO4-p53 sequestration for survival — different senescence contexts (replicative, oncogene-induced, DNA damage-induced, stress-induced) may use different anti-apoptotic mechanisms, and FOXO4-DRI's senolytic activity may be less effective in senescent cells driven by different mechanisms. The specificity of FOXO4-DRI for "senolytic" versus other apoptosis-inducing effects at higher doses has not been fully characterized in humans. The peptide's ability to reach tissue sites of senescence across the blood-brain barrier and other biological compartments is relevant for potential CNS senolytic applications but not well characterized. These mechanistic limitations are part of why the senolytic field has developed multiple compound classes targeting different vulnerabilities of senescent cells, rather than relying on a single pathway.
Overview
FOXO4-DRI is a synthetic 34-amino-acid D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53, with the specific goal of inducing apoptosis selectively in senescent cells. The compound was developed by the laboratory of Peter de Keizer at Erasmus Medical Center and reported in a landmark 2017 Cell paper that demonstrated FOXO4-DRI administration to aged mice produced measurable reductions in senescent cell burden, restored renal function, improved fur density and grooming behavior, and extended several markers of organismal health without apparent toxicity at effective doses (Baar et al., 2017). The publication was widely covered in mainstream science media and became one of the most cited demonstrations of targeted senolytic therapy as a plausible anti-aging strategy. The underlying biology is that cellular senescence — a state of permanent cell-cycle arrest induced by replicative exhaustion, DNA damage, oncogenic signaling, or mitochondrial dysfunction — accumulates with age in multiple tissues and contributes to tissue dysfunction through the senescence-associated secretory phenotype (SASP), a paracrine signature of pro-inflammatory cytokines, matrix-degrading proteases, and growth factors that damages neighboring cells and impairs tissue homeostasis. Selectively eliminating senescent cells while sparing non-senescent neighbors is the core concept of senolytic therapy, and multiple classes of molecules have been developed to pursue this goal: the dasatinib-quercetin combination, ABT-263 (navitoclax), fisetin, the p53 activator UBX0101 (now largely abandoned), and FOXO4-DRI represent distinct mechanistic strategies within the senolytic space (Kirkland & Tchkonia, 2020). FOXO4-DRI specifically targets a vulnerability identified in senescent cells: they depend on sequestration of p53 away from the mitochondrial outer membrane to avoid apoptosis, and this sequestration is maintained by a physical interaction between FOXO4 and p53 at specific nuclear sites. Disrupting the FOXO4-p53 interaction with FOXO4-DRI releases p53 to translocate to mitochondria, where it triggers the intrinsic apoptosis pathway in senescent cells that have accumulated pro-apoptotic signals but been held alive by the FOXO4-p53 sequestration. Non-senescent cells, which do not have the same accumulated pro-apoptotic signaling, are not killed by FOXO4-DRI administration (Baar et al., 2017; Bourgeois & Madl, 2018). The peptide is chemically distinctive because it is built as a D-retro-inverso (DRI) isomer, meaning it uses D-amino acids in reverse sequence compared to the parent L-peptide. This structural trick produces a molecule with roughly the same three-dimensional shape as the original but with complete protease resistance, because human proteases cannot recognize D-amino acid bonds. DRI peptides are used throughout the peptide-drug field when the natural L-peptide is too short-lived in vivo to be useful. The FOXO4-DRI sequence specifically is derived from the FOXO4 region that contacts p53, and the D-retro-inverso construction maintains the binding affinity while extending plasma and tissue half-life to useful ranges. The practical reality of FOXO4-DRI in April 2026 is that it remains an investigational research peptide with no approved human use, no clinical trials registered or published, and no pharmaceutical-grade manufacturing. Research-peptide vendors sell what they claim is FOXO4-DRI for "research purposes only," and a biohacker community has accumulated several years of self-experimentation experience with the compound. This entry covers the mechanism in detail, the original Baar et al. 2017 study and what it actually showed, subsequent work that has attempted to reproduce and extend the findings, the theoretical and practical concerns with self-administration, why the compound has not progressed to human trials despite its prominence, and what realistic thinking about FOXO4-DRI looks like in the context of the broader senolytic field.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
D-Arg-D-Gln-D-Cys-D-Met-D-Met-D-Leu-D-Asn-Gly-D-Phe-D-Ile-D-Ser-D-Asn-D-Met-D-Arg-D-Arg-D-Ser-D-Gln-D-Ala-D-Leu-D-Val-D-Lys-D-Ser-D-Gln-D-Gln-D-Pro-D-Pro-D-Thr-D-Glu-D-Asp-Gly-D-Pro
Molecular Mass
3587.0 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
FOXO4-DRI's senolytic mechanism creates a specific contraindication profile reflecting concerns about cancer, reproduction, acute illness, and drug interactions. Active malignancy is a complex contraindication. On one hand, senescent cells in the tumor microenvironment can promote tumor progression through SASP effects, suggesting senolytic clearance might be beneficial. On the other hand, some cancer cells use senescence as a transient survival strategy during chemotherapy, and senolytic clearance could potentially interact unpredictably with cancer treatment. FOXO4-DRI should not be used during active cancer treatment without explicit oncology supervision within a research protocol. Patients with a history of cancer under surveillance should also avoid FOXO4-DRI outside of clinical trial participation because effects on dormant disease and surveillance are unknown. Recent cancer treatment (within 12 months of completion) warrants oncologist consultation even if surveillance is unremarkable. Pregnancy and breastfeeding are absolute contraindications. Senescent cells play specific roles in embryonic development, placental function, and neonatal physiology, and systemic senolytic therapy during pregnancy or lactation could disrupt these processes with potentially serious consequences. Anyone trying to conceive should avoid FOXO4-DRI because effects on gametogenesis, fertility, and early embryonic development are uncharacterized. Children and adolescents should not use FOXO4-DRI because cellular senescence plays normal roles in growth, development, and tissue remodeling during this life stage. Active acute infection is a relative contraindication because the senolytic mechanism may interact with immune responses to infection. Senescent immune cells can contribute to chronic inflammation but may also provide protective functions during acute infection. FOXO4-DRI dosing during active infection is not advised; waiting for infection resolution before initiating a senolytic cycle is prudent. Recent major surgery or injury is a relative contraindication because senescent cells play transient positive roles in acute wound healing and tissue repair. Senolytic dosing during active recovery from significant injury could theoretically impair healing. A general guideline is to avoid senolytic dosing for at least 4-6 weeks after major surgery or significant injury; consult with a physician for specific timing. Organ transplant recipients on immunosuppression are at increased risk with any immunomodulatory intervention, and FOXO4-DRI effects on immune cell senescence and transplant rejection are completely uncharacterized. Avoid in this population. Autoimmune disease on immunomodulatory therapy is a relative contraindication because effects on immune cell populations (which include senescent cells) and inflammatory signaling are not characterized. Patients with active rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, psoriasis, or other autoimmune conditions should discuss FOXO4-DRI with their treating specialist before use. Significant cardiovascular disease is a relative contraindication because effects on cardiac and vascular tissue senescence are not well characterized in humans, and the response of impaired cardiovascular systems to senolytic dosing is unknown. Stable cardiovascular disease with good medical management may be compatible with cautious senolytic dosing under physician supervision; unstable disease is not. Significant hepatic or renal impairment warrants caution because peptide clearance pathways are not characterized in these settings, and altered pharmacokinetics could produce higher-than-intended exposure. Patients with significant hepatic or renal disease should consult their physician before use. Uncontrolled diabetes is a relative contraindication because senescent beta cells contribute to type 2 diabetes pathogenesis, and senolytic effects on beta cell function could theoretically alter glucose homeostasis in unpredictable ways. Patients with well-controlled diabetes on stable regimens may be able to use FOXO4-DRI with monitoring; unstable glycemia is not the right context for adding uncharacterized compounds. Bleeding disorders or anticoagulant therapy are not absolute contraindications for subcutaneous injection, but the risk of injection-site bruising or hematoma is elevated and warrants attention. Patients on warfarin, direct oral anticoagulants, or antiplatelet therapy should apply pressure after injection and watch for persistent bleeding. Known hypersensitivity to peptide products or to any component of the preparation (including bacteriostatic water preservative) is an absolute contraindication. Medications with potential interactions are largely uncharacterized because no drug-drug interaction studies exist. Theoretical interactions include: chemotherapy agents (as discussed above); corticosteroids (senescent cell effects on corticosteroid responsiveness); immunosuppressants; anti-apoptotic drugs (navitoclax, venetoclax); mTOR inhibitors (rapamycin/sirolimus — mechanistic overlap with senolytic effects); metformin (reported senolytic activity in some contexts); other senolytic agents (dasatinib, fisetin — see stacking discussion); and any drug with narrow therapeutic window that might be affected by altered cellular composition in clearance tissues. Patients on any complex medication regimen should discuss FOXO4-DRI with their physician and pharmacist before use. The final and most important contraindication is the absence of clinical oversight. Self-experimentation with an unvalidated research peptide without a knowledgeable physician who can monitor response, order appropriate labs, and evaluate adverse events does not meet the minimum safety standard for a compound with FOXO4-DRI's risk profile. This is not a specific medical contraindication — it is an infrastructure contraindication that applies regardless of personal health status. Finding a physician with expertise in senolytic therapy is difficult but possible; the effort to establish this clinical relationship before starting is worth more than the peptide itself.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$59.99
up to $129.99
$8.9990
3
4
vial
Tracking since Apr 6, 2026 · 2 data points
Price History
2 data pointsVendors Selling FOXO4-DRI
Limitless Biochem EU
Ion Peptide
VANDL Labs
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
View Full Dosage Guide →
Protocols, calculator & safety for FOXO4-DRI
Research Score
8 PubMed studies
Quality Indicators
Data Completeness
100%Research Credibility
Limited research available
Quick Facts
Molecular Weight
3587.0 g/mol
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What does FOXO4-DRI actually do at the cellular level?
FOXO4-DRI is a D-retro-inverso peptide that disrupts the interaction between FOXO4 transcription factor and p53 in senescent cells. In senescent cells, this interaction sequesters p53 away from mitochondria, preventing apoptosis. Disrupting the interaction releases p53, which relocates to mitochondria and triggers apoptosis. Non-senescent cells lack the accumulated mitochondrial priming that makes p53 release lethal, so they are spared. This produces selective killing of senescent cells (Baar et al., 2017; Bourgeois & Madl, 2018).
Has FOXO4-DRI been tested in humans?
No. As of April 2026, no Phase 1 or later human clinical trials of FOXO4-DRI have been published, no IND applications have been publicly disclosed, and no registered trials appear on ClinicalTrials.gov. All human use is self-experimentation with research-chemical vendor supply.
How is FOXO4-DRI different from other senolytics like fisetin or dasatinib+quercetin?
Different senolytics target different vulnerabilities of senescent cells. Dasatinib-quercetin affects SRC/TYK family kinases and Bcl-XL. Navitoclax (ABT-263) targets Bcl-2/Bcl-XL family proteins. Fisetin acts through multiple mechanisms including Bcl-XL inhibition. FOXO4-DRI specifically disrupts FOXO4-p53 sequestration. Different senolytics have different selectivity profiles for different senescent cell types, which is why some researchers advocate for rotating or combining senolytics (Kirkland & Tchkonia, 2020).
What did the original Baar et al. 2017 study show?
The Cell paper demonstrated that FOXO4-DRI selectively killed senescent cells in culture, reduced senescent cell burden in doxorubicin-treated mice with improved tissue function, and in naturally aged mice improved fur density, renal function, and activity levels. The improvements were modest in absolute terms — the aged mice did not become young — but they were consistent and mechanism-appropriate (Baar et al., 2017). The study established FOXO4-DRI as a proof-of-concept senolytic but did not demonstrate human efficacy or safety.
What dose of FOXO4-DRI do people use?
Self-report communities describe doses ranging from 2-15 mg per dose subcutaneously, typically 5 mg for a standard dose. Cycles are 3-7 consecutive days of dosing repeated every 2-6 months. These doses are extrapolated from rodent studies using body surface area scaling and have no clinical validation in humans.
Why do some people report flu-like symptoms after FOXO4-DRI?
Flu-like symptoms (fatigue, low-grade fever, mild joint or muscle aches, malaise) are commonly reported in the 24-72 hours after senolytic dosing. The self-interpreted explanation is that senescent cell clearance releases SASP cytokines and cellular contents into circulation, producing a transient inflammatory response. An alternative explanation is pyrogen contamination in research-chemical supply (endotoxin from manufacturing processes). Distinguishing between these explanations without batch-specific analytical testing is difficult.
Can FOXO4-DRI be combined with other senolytics?
Combining multiple senolytics on the same day compounds unknown risks and is not recommended. Rotating between different senolytics across cycles (fisetin in one cycle, FOXO4-DRI in the next, dasatinib+quercetin in another) is a practice some users pursue on the theory that different senolytics clear different subsets of senescent cells. Clinical evidence for this combination approach is absent.
Is FOXO4-DRI safe for people with cancer history?
FOXO4-DRI should not be used by people with active cancer, recently treated cancer (within 12 months), or under active cancer surveillance without explicit oncology consultation. Senescence serves both tumor-suppressor and tumor-promoter functions depending on context, and the net effect of senolytic therapy on cancer risk in humans is unknown. The theoretical concerns warrant conservative avoidance in anyone with cancer risk.
Do I need a physician to use FOXO4-DRI?
Yes, if you are going to use it responsibly. Self-administration of an unvalidated research peptide without physician monitoring does not meet the minimum safety standard for a compound with FOXO4-DRI's risk profile. The physician should know about the use, be able to order and interpret appropriate labs, and be able to evaluate any adverse effects. Finding a clinician with expertise in senolytic pharmacology is difficult but not impossible; this is not a compound for unsupervised use.
What is the bottom line on whether FOXO4-DRI works in humans?
Unknown. The preclinical evidence is mechanistically compelling, but no human clinical trials have been conducted, so efficacy in humans cannot be claimed. The broader senolytic field has produced some positive human results (dasatinib+quercetin in kidney disease, fisetin in inflammatory conditions) and some negative results (UBX0101 in osteoarthritis), suggesting senolytic strategy is not uniformly effective. FOXO4-DRI sits in the intriguing-but-unvalidated category alongside many other preclinical compounds. For humans interested in senolytic therapy, fisetin and (under physician supervision) dasatinib-quercetin are the options with actual human data.
Research Tools
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.